A cost-effectiveness and budget impact analysis of apremilast in patients with psoriatic arthritis in Italy.
Conclusion: The use of apremilast as a first option before the use of biologic agents may represent a cost-effective treatment strategy for patients with PsA who fail to respond to, or are intolerant to, previous DMARD therapy. In addition, based on a budget impact perspective, the use of apremilast may lead to cost savings to the Italian healthcare system.
PMID: 31856609 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Arthritis | Economics | Health Management | Italy Health | Psoriatic Arthritis | Rheumatology | Study | UK Health